There is little doubt that Abbott who reported earnings this morning is selling FreeStyle Libre’s. As per today’s press release;
“In Diabetes Care, where sales increased 39.8 percent on a reported basis and 33.6 percent on an organic basis, growth was led by continued rapid market uptake of FreeStyle® Libre, Abbott's revolutionary sensor-based continuous glucose monitoring (CGM) system, which removes the need for routine fingersticks1 for people with diabetes.”
Before we go on it wasn’t that long ago that diabetes care was dying nor was that long ago when the Navigator Abbott’s . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.